Your browser doesn't support javascript.
loading
Show: 20 | 50 | 100
Results 1 - 20 de 3.467
Filter
1.
PLoS One ; 19(6): e0303900, 2024.
Article in English | MEDLINE | ID: mdl-38843120

ABSTRACT

BACKGROUND: Candesartan cilexetil (CC) is a selective angiotensin II receptor antagonist widely used to treat hypertension. CC is a substrate of P-glycoprotein (P-gp), causing its efflux to the intestinal lumen. It is also practically insoluble in water and has low oral bioavailability (14%). Thus, the current study aims to improve the in vitro dissolution of CC by developing solid dispersion systems (SDSs) and corroborating the in vitro results using a simulated pharmacokinetics study. METHODS: The SDSs were prepared using polyvinyl pyrrolidone (PVP) as a water-soluble polymer, Eudragit E100 (EE100) as a pH-dependent soluble carrier, and a combination of these two polymers. The saturation solubility and the dissolution rate studies of the prepared systems in three dissolution media were performed. The optimized system SE-EE5 was selected for further investigations, including DSC, XRD, FTIR, FESEM, DLS, TSEM, IVIVC convolution study, and stability studies. RESULTS: The solubility of CC significantly increased by a factor of 27,037.344 when formulated as a solid dispersion matrix using EE100 at a ratio of 1:5 (w/w) drug to polymer (SE-EE5 SD), compared to the solubility of the pure drug. The mechanism of solubility and dissolution rate enhancement of CC by the optimized SDS was found to be via the conversion of the crystalline CC into the amorphous form as well as nanoparticles formation upon dissolution at a pH below 5. The instrumental analysis tests showed good compatibility between CC and EE100 and there was no chemical interaction between the drug and the polymer. Moreover, the stability tests confirmed that the optimized system was stable after three months of storage at 25°C. CONCLUSION: The utilization of the solid dispersion technique employing EE 100 polymer as a matrix demonstrates significant success in enhancing the solubility, dissolution, and subsequently, the bioavailability of water-insoluble drugs like CC.


Subject(s)
Benzimidazoles , Biphenyl Compounds , Polymers , Solubility , Tetrazoles , Benzimidazoles/chemistry , Benzimidazoles/pharmacokinetics , Tetrazoles/chemistry , Tetrazoles/pharmacokinetics , Biphenyl Compounds/chemistry , Biphenyl Compounds/pharmacokinetics , Polymers/chemistry , Polymers/pharmacokinetics , Povidone/chemistry , Water/chemistry , Hydrogen-Ion Concentration , Biological Availability , Drug Stability , Drug Liberation , Acrylates
2.
Drug Dev Res ; 85(4): e22218, 2024 Jun.
Article in English | MEDLINE | ID: mdl-38825827

ABSTRACT

We report herein, the design and synthesis of benzimidazole-oxadiazole derivatives as new inhibitors for vascular endothelial growth factor receptor-2 (VEGFR-2). The designed members were assessed for their in vitro anticancer activity against three cancer cell lines and two normal cell lines; A549, MCF-7, PANC-1, hTERT-HPNE and CCD-19Lu. Compounds 4c and 4d were found to be the most effective compounds against three cancer cell lines. Compounds 4c and 4d were then tested for their in vitro VEGFR-2 inhibitory activity, safety profiles, and selectivity indices using the normal hTERT-HPNE and CCD-19Lu cell lines. It was determined that compound 4c was the most effective and safe member of the produced chemical family. Vascular endothelial growth factor A (VEGFA) immunolocalizations of compounds 4c and 4d were evaluated relative to control by VEGFA immunofluorescence staining. Compounds 4c and 4d inhibited VEGFR-2 enzyme with half-maximal inhibitory concentration values of 0.475 ± 0.021 and 0.618 ± 0.028 µM, respectively. Molecular docking of the target compounds was carried out in the active site of VEGFR-2 (Protein Data Bank: 4ASD).


Subject(s)
Antineoplastic Agents , Benzimidazoles , Molecular Docking Simulation , Oxadiazoles , Vascular Endothelial Growth Factor Receptor-2 , Humans , Vascular Endothelial Growth Factor Receptor-2/antagonists & inhibitors , Vascular Endothelial Growth Factor Receptor-2/metabolism , Oxadiazoles/pharmacology , Oxadiazoles/chemistry , Oxadiazoles/chemical synthesis , Antineoplastic Agents/pharmacology , Antineoplastic Agents/chemical synthesis , Antineoplastic Agents/chemistry , Benzimidazoles/pharmacology , Benzimidazoles/chemistry , Benzimidazoles/chemical synthesis , Protein Kinase Inhibitors/pharmacology , Protein Kinase Inhibitors/chemical synthesis , Protein Kinase Inhibitors/chemistry , Cell Line, Tumor , Structure-Activity Relationship , Drug Screening Assays, Antitumor , Vascular Endothelial Growth Factor A/metabolism , Vascular Endothelial Growth Factor A/antagonists & inhibitors , Cell Proliferation/drug effects
3.
Molecules ; 29(10)2024 May 20.
Article in English | MEDLINE | ID: mdl-38792260

ABSTRACT

(1) Background: The aim of the work is the evaluation of in vitro antiproliferative and pro-apoptotic activity of four benzimidazole derivatives containing colchicine-like and catechol-like moieties with methyl group substitution in the benzimidazole ring against highly invasive breast cancer cell line MDA-MB-231 and their related impairment of tubulin dynamics. (2) Methods: The antiproliferative activity was assessed with the MTT assay. Alterations in tubulin polymerization were evaluated with an in vitro tubulin polymerization assay and a docking analysis. (3) Results: All derivatives showed time-dependent cytotoxicity with IC50 varying from 40 to 60 µM after 48 h and between 13 and 20 µM after 72 h. Immunofluorescent and DAPI staining revealed the pro-apoptotic potential of benzimidazole derivatives and their effect on tubulin dynamics in living cells. Compound 5d prevented tubulin aggregation and blocked mitosis, highlighting the importance of the methyl group and the colchicine-like fragment. (4) Conclusions: The benzimidazole derivatives demonstrated moderate cytotoxicity towards MDA-MB-231 by retarding the initial phase of tubulin polymerization. The derivative 5d containing a colchicine-like moiety and methyl group substitution in the benzimidazole ring showed potential as an antiproliferative agent and microtubule destabilizer by facilitating faster microtubule aggregation and disrupting cellular and nuclear integrity.


Subject(s)
Antineoplastic Agents , Apoptosis , Benzimidazoles , Breast Neoplasms , Cell Proliferation , Tubulin , Humans , Tubulin/metabolism , Cell Proliferation/drug effects , Apoptosis/drug effects , Breast Neoplasms/drug therapy , Breast Neoplasms/metabolism , Breast Neoplasms/pathology , Cell Line, Tumor , Benzimidazoles/pharmacology , Benzimidazoles/chemistry , Antineoplastic Agents/pharmacology , Antineoplastic Agents/chemistry , Antineoplastic Agents/chemical synthesis , Female , Hydrazones/pharmacology , Hydrazones/chemistry , Hydrazones/chemical synthesis , Molecular Docking Simulation , Tubulin Modulators/pharmacology , Tubulin Modulators/chemistry , Structure-Activity Relationship , Polymerization , Molecular Structure
4.
J Inorg Biochem ; 257: 112603, 2024 Aug.
Article in English | MEDLINE | ID: mdl-38749081

ABSTRACT

Numerous heterocyclic moieties serve as the foundational structure for clinically employed drugs, underscoring the significance of heterocycles in the innovation of pharmacologically active compounds. In the present investigation, a heterocyclic skeleton of thiophene-clubbed benzimidazole (tmb) was developed and utilized to synthesize seven novel series of metal (M(II) = Co, Ni, Cu, and Zn) complexes to explore diverse applications including pharmacological and photocatalytic performance. A sharp singlet peak appeared at 5.72 ppm (tmb) and 5.94 ppm for the Zn(II)-tmb complex corresponding to -CH2 protons, as evidenced by 1H NMR results, confirming the formation of targeted compounds. Antimicrobial assay and docking studies confirmed that the mixed metal complex; [Cu(tmb)2(1,10-phen)Cl2] possesses the highest activity and displayed significant biofilm inhibition, achieving 86.35 and 89.8% at concentrations of 1 and 0.020 mg/mL, respectively against E. coli. Furthermore, the photocatalytic activity was monitored by the degradation of methylene blue dye under direct sunlight and [Cu(tmb)2Cl2] exhibited a maximum degradation efficiency of 96.15% in 45 min. These findings could serve as inspiration for the development of benzimidazole-based metal complexes as effective anti-biofilm and photocatalytic agents.


Subject(s)
Coordination Complexes , Escherichia coli , Light , Coordination Complexes/chemistry , Coordination Complexes/pharmacology , Coordination Complexes/chemical synthesis , Catalysis , Escherichia coli/drug effects , Benzimidazoles/chemistry , Anti-Bacterial Agents/chemistry , Anti-Bacterial Agents/pharmacology , Biofilms/drug effects , Heterocyclic Compounds/chemistry , Sulfur/chemistry , Photochemical Processes , Molecular Docking Simulation , Microbial Sensitivity Tests
5.
J Med Chem ; 67(11): 8730-8756, 2024 Jun 13.
Article in English | MEDLINE | ID: mdl-38817193

ABSTRACT

The secretory glutaminyl cyclase (sQC) and Golgi-resident glutaminyl cyclase (gQC) are responsible for N-terminal protein pyroglutamation and associated with various human diseases. Although several sQC/gQC inhibitors have been reported, only one inhibitor, PQ912, is currently undergoing clinic trials for the treatment of Alzheimer's disease. We report an X-ray crystal structure of sQC complexed with PQ912, revealing that the benzimidazole makes "anchor" interactions with the active site zinc ion and catalytic triad. Structure-guided design and optimization led to a series of new benzimidazole derivatives exhibiting nanomolar inhibition for both sQC and gQC. In a MPTP-induced Parkinson's disease (PD) mouse model, BI-43 manifested efficacy in mitigating locomotor deficits through reversing dopaminergic neuronal loss, reducing microglia, and decreasing levels of the sQC/gQC substrates, α-synuclein, and CCL2. This study not only offers structural basis and new leads for drug discovery targeting sQC/gQC but also provides evidence supporting sQC/gQC as potential targets for PD treatment.


Subject(s)
Aminoacyltransferases , Benzimidazoles , Enzyme Inhibitors , Animals , Aminoacyltransferases/antagonists & inhibitors , Aminoacyltransferases/metabolism , Benzimidazoles/chemistry , Benzimidazoles/pharmacology , Benzimidazoles/chemical synthesis , Crystallography, X-Ray , Mice , Enzyme Inhibitors/pharmacology , Enzyme Inhibitors/chemistry , Enzyme Inhibitors/chemical synthesis , Enzyme Inhibitors/therapeutic use , Structure-Activity Relationship , Disease Models, Animal , Parkinson Disease/drug therapy , Parkinson Disease/metabolism , Humans , Mice, Inbred C57BL , Drug Discovery , Male , Models, Molecular
6.
ACS Infect Dis ; 10(6): 2262-2275, 2024 Jun 14.
Article in English | MEDLINE | ID: mdl-38787329

ABSTRACT

The prevalence of Helicobacter pylori infection has been increasing rapidly due to the genetic heterogeneity and antibacterial resistance shown by the bacteria, affecting over 50% of the world population and over 80% of the Indian population, in particular. In this regard, novel drug targets are currently being explored, one of which is the crucial metabolic enzyme inosine-5'-monophosphate dehydrogenase (IMPDH) involved in the de novo nucleotide biosynthesis pathway, in order to combat the infection and devise efficient therapeutic strategies. The present study reports the development of methylpyrazole-substituted benzimidazoles as small molecule inhibitors of H. pylori IMPDH with a nanomolar range of enzyme inhibition. A set of 19 small molecules have been designed, synthesized, and further evaluated for their inhibitory potential against H. pylori IMPDH using in silico, in vitro, biochemical, and biophysical techniques. Compound 7j was found to inhibit H. pylori IMPDH with an IC50 value of 0.095 ± 0.023 µM, which is close to 1.5-fold increase in the inhibitory activity, in comparison to the previously reported benzimidazole-based hit C91. Moreover, kinetic characterization has provided significant insights into the uncompetitive inhibition shown by these small molecules on H. pylori IMPDH, thus providing details about the enzyme inhibition mechanism. In conclusion, methylpyrazole-based small molecules indicate a promising path to develop cheap and bioavailable drugs to efficiently treat H. pylori infection in the coming years, in comparison to the currently available therapy.


Subject(s)
Anti-Bacterial Agents , Benzimidazoles , Helicobacter Infections , Helicobacter pylori , IMP Dehydrogenase , Pyrazoles , Helicobacter pylori/drug effects , Helicobacter pylori/enzymology , Benzimidazoles/pharmacology , Benzimidazoles/chemistry , Helicobacter Infections/drug therapy , Helicobacter Infections/microbiology , Pyrazoles/pharmacology , Pyrazoles/chemistry , IMP Dehydrogenase/antagonists & inhibitors , IMP Dehydrogenase/metabolism , Anti-Bacterial Agents/pharmacology , Anti-Bacterial Agents/chemistry , Enzyme Inhibitors/pharmacology , Enzyme Inhibitors/chemistry , Enzyme Inhibitors/chemical synthesis , Structure-Activity Relationship , Humans , Microbial Sensitivity Tests , Molecular Docking Simulation , Kinetics
7.
Eur J Med Chem ; 273: 116507, 2024 Jul 05.
Article in English | MEDLINE | ID: mdl-38776806

ABSTRACT

Careful recruitment of the components of the HDAC inhibitory template culminated in veliparib-based anilide 8 that elicited remarkable cell growth inhibitory effects against HL-60 cell lines mediated via dual modulation of PARP [(IC50 (PARP1) = 0.02 nM) and IC50 (PARP2) = 1 nM)] and HDACs (IC50 value = 0.05, 0.147 and 0.393 µM (HDAC1, 2 and 3). Compound 8 downregulated the expression levels of signatory biomarkers of PARP and HDAC inhibition. Also, compound 8 arrested the cell cycle at the G0/G1 phase and induced autophagy. Polymer nanoformulation (mPEG-PCl copolymeric micelles loaded with compound 8) was prepared by the nanoprecipitation technique. The mPEG-PCL diblock copolymer was prepared by ring-opening polymerization method using stannous octoate as a catalyst. The morphology of the compound 8@mPEG-PCL was examined using TEM and the substance was determined to be monodispersed, spherical in form, and had an average diameter of 138 nm. The polymer nanoformulation manifested pH-sensitive behaviour as a greater release of compound 8 was observed at 6.2 pH as compared to 7.4 pH mimicking physiological settings. The aforementioned findings indicate that the acidic pH of the tumour microenvironment might stimulate the nanomedicine release which in turn can attenuate the off-target effects precedentially claimed to be associated with HDAC inhibitors.


Subject(s)
Antineoplastic Agents , Benzimidazoles , Cell Proliferation , Drug Design , Drug Screening Assays, Antitumor , Polyethylene Glycols , Humans , Hydrogen-Ion Concentration , Antineoplastic Agents/pharmacology , Antineoplastic Agents/chemistry , Antineoplastic Agents/chemical synthesis , Benzimidazoles/chemistry , Benzimidazoles/pharmacology , Benzimidazoles/chemical synthesis , Cell Proliferation/drug effects , Polyethylene Glycols/chemistry , HL-60 Cells , Nanoparticles/chemistry , Molecular Structure , Micelles , Structure-Activity Relationship , Dose-Response Relationship, Drug , Polyesters/chemistry , Polyesters/pharmacology , Polyesters/chemical synthesis , Histone Deacetylase Inhibitors/chemistry , Histone Deacetylase Inhibitors/pharmacology , Histone Deacetylase Inhibitors/chemical synthesis , Polymers/chemistry , Polymers/pharmacology , Polymers/chemical synthesis
8.
Mikrochim Acta ; 191(6): 348, 2024 05 28.
Article in English | MEDLINE | ID: mdl-38805077

ABSTRACT

A novel aptamer-based sensor was developed using the signal amplification strategy of ring-opening metathesis polymerization (ROMP) and polyethyleneimine modified graphene oxide to achieve trace detection of carbendazim (CBZ). The dual identification of aptamer and antibody was used to avoid false positive results and improve the selectivity. Polyethyleneimine modified graphene oxide (GO-PEI), as a substrate material with excellent conductivity, was modified on the surface of a glassy carbon electrode (GCE) to increase the grafting amount of aptamer on the electrode surface. Moreover, a large number of cyclopentenyl ferrocene (CFc) was aggregated to form long polymer chains through ring-opening metathesis polymerization (ROMP), so as to significantly improve the detection sensitivity of the biosensor. The linear range of this sensor was 1 pg/mL-100 ng/mL with a detection limit as low as 7.80 fg/mL. The sensor exhibited excellent reproducibility and stability, and also achieved satisfactory results in actual sample detection. The design principle of such a sensor could provide innovative ideas for sensors in the detection of other types of targets.


Subject(s)
Aptamers, Nucleotide , Benzimidazoles , Biosensing Techniques , Carbamates , Electrochemical Techniques , Graphite , Limit of Detection , Polyethyleneimine , Polymerization , Graphite/chemistry , Carbamates/chemistry , Carbamates/analysis , Electrochemical Techniques/methods , Electrochemical Techniques/instrumentation , Polyethyleneimine/chemistry , Biosensing Techniques/methods , Benzimidazoles/chemistry , Aptamers, Nucleotide/chemistry , Electrodes , Reproducibility of Results
9.
Nat Commun ; 15(1): 3367, 2024 May 08.
Article in English | MEDLINE | ID: mdl-38719808

ABSTRACT

Soil-transmitted helminths (STHs) are major pathogens infecting over a billion people. There are few classes of anthelmintics and there is an urgent need for new drugs. Many STHs use an unusual form of anaerobic metabolism to survive the hypoxic conditions of the host gut. This requires rhodoquinone (RQ), a quinone electron carrier. RQ is not made or used by vertebrate hosts making it an excellent therapeutic target. Here we screen 480 structural families of natural products to find compounds that kill Caenorhabditis elegans specifically when they require RQ-dependent metabolism. We identify several classes of compounds including a family of species-selective inhibitors of mitochondrial respiratory complex I. These identified complex I inhibitors have a benzimidazole core and we determine key structural requirements for activity by screening 1,280 related compounds. Finally, we show several of these compounds kill adult STHs. We suggest these species-selective complex I inhibitors are potential anthelmintics.


Subject(s)
Anthelmintics , Caenorhabditis elegans , Electron Transport Complex I , Ubiquinone/analogs & derivatives , Animals , Anthelmintics/pharmacology , Anthelmintics/chemistry , Electron Transport Complex I/antagonists & inhibitors , Electron Transport Complex I/metabolism , Caenorhabditis elegans/metabolism , Benzimidazoles/pharmacology , Benzimidazoles/chemistry , Species Specificity , Quinones/chemistry , Quinones/pharmacology , Quinones/metabolism , Biological Products/pharmacology , Biological Products/chemistry
10.
J Chromatogr A ; 1726: 464975, 2024 Jul 05.
Article in English | MEDLINE | ID: mdl-38735118

ABSTRACT

In conventional chromatographic ligand screening, underperforming ligands are often dismissed. However, this practice may inadvertently overlook potential opportunities. This study aims to investigate whether these underperforming ligands can be repurposed as valuable assets. Hydrophobic charge-induction chromatography (HCIC) is chosen as the validation target for its potential as an innovative chromatographic mode. A novel dual-ligand approach is employed, combining two suboptimal ligands (5-Aminobenzimidazole and Tryptamine) to explore enhanced performance and optimization prospects. Various dual-ligand HCIC resins with different ligand densities were synthesized by adjusting the ligand ratio and concentration. The resins were characterized to assess appearance, functional groups, and pore features using SEM, FTIR, and ISEC techniques. Performance assessments were conducted using single-ligand mode resins as controls, evaluating the selectivity against human immunoglobulin G and human serum albumin. Static adsorption experiments were performed to understand pH and salt influence on adsorption. Breakthrough experiments were conducted to assess dynamic adsorption capacity of the novel resin. Finally, chromatographic separation using human serum was performed to evaluate the purity and yield of the resin. Results indicated that the dual-ligand HCIC resin designed for human antibodies demonstrates exceptional selectivity, surpassing not only single ligand states but also outperforming certain high-performing ligand types, particularly under specific salt and pH conditions. Ultimately, a high yield of 83.9 % and purity of 96.7 % were achieved in the separation of hIgG from human serum with the dual-ligand HCIC, significantly superior to the single-ligand resins. In conclusion, through rational design and proper operational conditions, the dual-ligand mode can revitalize underutilized ligands, potentially introducing novel and promising chromatographic modes.


Subject(s)
Hydrophobic and Hydrophilic Interactions , Immunoglobulin G , Ligands , Humans , Adsorption , Immunoglobulin G/chemistry , Immunoglobulin G/blood , Tryptamines/chemistry , Chromatography, Liquid/methods , Benzimidazoles/chemistry , Hydrogen-Ion Concentration
11.
Molecules ; 29(9)2024 May 04.
Article in English | MEDLINE | ID: mdl-38731629

ABSTRACT

This work presents the design, synthesis and biological activity of novel N-substituted benzimidazole carboxamides bearing either a variable number of methoxy and/or hydroxy groups. The targeted carboxamides were designed to investigate the influence of the number of methoxy and/or hydroxy groups, the type of substituent placed on the N atom of the benzimidazole core and the type of substituent placed on the benzimidazole core on biological activity. The most promising derivatives with pronounced antiproliferative activity proved to be N-methyl-substituted derivatives with hydroxyl and methoxy groups at the phenyl ring and cyano groups on the benzimidazole nuclei with selective activity against the MCF-7 cell line (IC50 = 3.1 µM). In addition, the cyano-substituted derivatives 10 and 11 showed strong antiproliferative activity against the tested cells (IC50 = 1.2-5.3 µM). Several tested compounds showed significantly improved antioxidative activity in all three methods compared to standard BHT. In addition, the antioxidative activity of 9, 10, 32 and 36 in the cells generally confirmed their antioxidant ability demonstrated in vitro. However, their antiproliferative activity was not related to their ability to inhibit oxidative stress nor to their ability to induce it. Compound 8 with two hydroxy and one methoxy group on the phenyl ring showed the strongest antibacterial activity against the Gram-positive strain E. faecalis (MIC = 8 µM).


Subject(s)
Antineoplastic Agents , Antioxidants , Benzimidazoles , Cell Proliferation , Drug Design , Benzimidazoles/chemistry , Benzimidazoles/pharmacology , Benzimidazoles/chemical synthesis , Humans , Cell Proliferation/drug effects , Antineoplastic Agents/pharmacology , Antineoplastic Agents/chemical synthesis , Antineoplastic Agents/chemistry , MCF-7 Cells , Antioxidants/pharmacology , Antioxidants/chemical synthesis , Antioxidants/chemistry , Structure-Activity Relationship , Anti-Bacterial Agents/pharmacology , Anti-Bacterial Agents/chemical synthesis , Anti-Bacterial Agents/chemistry , Amides/chemistry , Amides/pharmacology , Amides/chemical synthesis , Molecular Structure , Microbial Sensitivity Tests , Oxidative Stress/drug effects
12.
Int J Mol Sci ; 25(10)2024 May 07.
Article in English | MEDLINE | ID: mdl-38791117

ABSTRACT

Antimicrobial resistance (AMR) is one of the biggest threats in modern times. It was estimated that in 2019, 1.27 million deaths occurred around the globe due to AMR. Methicillin-resistant Staphylococcus aureus (MRSA) strains, a pathogen considered of high priority by the World Health Organization, have proven to be resistant to most of the actual antimicrobial treatments. Therefore, new treatments are required to be able to manage this increasing threat. Under this perspective, an important metabolic pathway for MRSA survival, and absent in mammals, is the shikimate pathway, which is involved in the biosynthesis of chorismate, an intermediate for the synthesis of aromatic amino acids, folates, and ubiquinone. Therefore, the enzymes of this route have been considered good targets to design novel antibiotics. The fifth step of the route is performed by shikimate kinase (SK). In this study, an in-house chemical library of 170 benzimidazole derivatives was screened against MRSA shikimate kinase (SaSK). This effort led to the identification of the first SaSK inhibitors, and the two inhibitors with the greatest inhibition activity (C1 and C2) were characterized. Kinetic studies showed that both compounds were competitive inhibitors with respect to ATP and non-competitive for shikimate. Structural analysis through molecular docking and molecular dynamics simulations indicated that both inhibitors interacted with ARG113, an important residue involved in ATP binding, and formed stable complexes during the simulation period. Biological activity evaluation showed that both compounds were able to inhibit the growth of a MRSA strain. Mitochondrial assays showed that both compounds modify the activity of electron transport chain complexes. Finally, ADMETox predictions suggested that, in general, C1 and C2 can be considered as potential drug candidates. Therefore, the benzimidazole derivatives reported here are the first SaSK inhibitors, representing a promising scaffold and a guide to design new drugs against MRSA.


Subject(s)
Benzimidazoles , Methicillin-Resistant Staphylococcus aureus , Molecular Docking Simulation , Phosphotransferases (Alcohol Group Acceptor) , Methicillin-Resistant Staphylococcus aureus/drug effects , Methicillin-Resistant Staphylococcus aureus/enzymology , Phosphotransferases (Alcohol Group Acceptor)/antagonists & inhibitors , Phosphotransferases (Alcohol Group Acceptor)/metabolism , Phosphotransferases (Alcohol Group Acceptor)/chemistry , Benzimidazoles/pharmacology , Benzimidazoles/chemistry , Kinetics , Anti-Bacterial Agents/pharmacology , Anti-Bacterial Agents/chemistry , Molecular Dynamics Simulation , Enzyme Inhibitors/pharmacology , Enzyme Inhibitors/chemistry , Humans , Microbial Sensitivity Tests , Bacterial Proteins/antagonists & inhibitors , Bacterial Proteins/metabolism , Bacterial Proteins/chemistry
13.
ACS Appl Bio Mater ; 7(5): 3330-3336, 2024 05 20.
Article in English | MEDLINE | ID: mdl-38701398

ABSTRACT

The threat of bacterial infections, especially drug-resistant strains, to human health necessitates the development of high-efficient, broad-spectrum and nonantibiotic nanodisinfectant. However, the effect of interfacial charge on the antibacterial properties of nanodisinfectant remains a mystery, which greatly limits the development of highly antibacterial active nanodisinfectant. Herein, we developed three types of ultrasmall (d < 3 nm) gold-nanoparticles (AuNPs) modified with 5-carboxylic(C)/methoxy(M)amino(A)/-2-mercaptobenzimidazole (C/M/A MB) to investigate their interfacial charge on antibacterial performance. Our results showed that both the electropositive AMB-AuNPs and electronegative CMB-AuNPs exhibited no antibacterial activity against both Gram-positive (G+) and Gram-negative (G-) bacteria. However, the electroneutral MMB-AuNPs exhibited unique antibacterial performance against both G+ and G- bacteria, even against methicillin-resistant Staphylococcus aureus (MRSA). Mechanistic investigation revealed a multipathway synergistic bacteriostatic mechanism involving MMB-AuNPs inducing damage to bacterial cell membranes, disruption of membrane potential and downregulation of ATP levels, ultimately leading to bacterial demise. Furthermore, two additional electroneutral AuNPs modified with 5-methyl-2-mercaptobenzimidazole (mMB-AuNPs) and 5-ethoxy-2-mercaptobenzimidazole (EMB-AuNPs) also demonstrated commendable antibacterial efficacy against E. coli, S. aureus, and MRSA; however, their performance was comparatively inferior to that of MMB-AuNPs. This work provides valuable insights for the development of high-performance antibacterial nanomaterials.


Subject(s)
Anti-Bacterial Agents , Benzimidazoles , Gold , Metal Nanoparticles , Microbial Sensitivity Tests , Particle Size , Gold/chemistry , Gold/pharmacology , Anti-Bacterial Agents/pharmacology , Anti-Bacterial Agents/chemistry , Anti-Bacterial Agents/chemical synthesis , Metal Nanoparticles/chemistry , Benzimidazoles/chemistry , Benzimidazoles/pharmacology , Materials Testing , Biocompatible Materials/chemistry , Biocompatible Materials/pharmacology , Methicillin-Resistant Staphylococcus aureus/drug effects , Drug Resistance, Bacterial/drug effects
14.
Drug Des Devel Ther ; 18: 1035-1052, 2024.
Article in English | MEDLINE | ID: mdl-38585255

ABSTRACT

Introduction: The paper presents the results of a study on the first synthesized benzimidazole derivatives obtained from labile nature carboxylic acids. The synthesis conditions of these substances were studied, their structure was proved, and some components were found to have sugar-reducing activity on the model of alloxan diabetes in rats. Methods: The study used molecular modeling methods such as docking based on the evolutionary model (igemdock), RP_HPLC method to monitor the synthesis reaction, and 1H NMR and 13C NMR, and other methods of organic chemistry to confirm the structures of synthesized substances. Results & Discussion: The docking showed that the ursodeoxycholic acid benzimidazole derivatives have high tropics to all imidazoline receptor carriers (PDB ID: 2XCG, 2bk3, 3p0c, 1QH4). The ursodeoxycholic acid benzimidazole derivative and arginine and histidine benzimidazole derivatives showed the highest sugar-lowering activity in the experiment on alloxan-diabetic rats. For these derivatives, the difference in glucose levels of treated rats was significant against untreated control. Therefore, the new derivatives of benzimidazole and labile natural organic acids can be used to create new classes of imidazoline receptor inhibitors for the treatment of diabetes mellitus and hypertension.


Subject(s)
Diabetes Mellitus, Experimental , Hypoglycemic Agents , Rats , Animals , Hypoglycemic Agents/chemistry , Structure-Activity Relationship , Imidazoline Receptors , Diabetes Mellitus, Experimental/chemically induced , Diabetes Mellitus, Experimental/drug therapy , Ursodeoxycholic Acid , Benzimidazoles/chemistry , Sugars , Molecular Docking Simulation , Molecular Structure
15.
Sci Rep ; 14(1): 9598, 2024 04 26.
Article in English | MEDLINE | ID: mdl-38671063

ABSTRACT

Allergic conjunctivitis (AC) is the most common form of allergic eye disease and an increasingly prevalent condition. Topical eye drop treatments are the usual approach for managing AC, although their impact on the ocular surface is not frequently investigated. The aim of this study was to perform a comparative physicochemical characterization, and in vitro biological evaluations in primary conjunctival and corneal epithelial cells of the new multidose preservative-free bilastine 0.6% and main commercially available eye drops. MTT assay was used to measure cell viability; oxidative stress was analyzed with a ROS-sensitive probe; and apoptosis was evaluated monitoring caspase 3/7 activation. Differences in pH value, osmolarity, viscosity and phosphate levels were identified. Among all formulations, bilastine exhibited pH, osmolarity and viscosity values closer to tear film (7.4, 300 mOsm/l and ~ 1.5-10 mPa·s, respectively), and was the only phosphates-free solution. Single-dose ketotifen did not induce ROS production, and single-dose azelastine and bilastine only induced a mild increase. Bilastine and single-dose ketotifen and azelastine showed high survival rates attributable to the absence of preservative in its formulation, not inducing caspase-3/7-mediated apoptosis after 24 h. Our findings support the use of the new bilastine 0.6% for treating patients with AC to preserve and maintain the integrity of the ocular surface.


Subject(s)
Apoptosis , Benzimidazoles , Caspase 3 , Cell Survival , Ophthalmic Solutions , Preservatives, Pharmaceutical , Ophthalmic Solutions/pharmacology , Humans , Preservatives, Pharmaceutical/pharmacology , Cell Survival/drug effects , Benzimidazoles/pharmacology , Benzimidazoles/chemistry , Caspase 3/metabolism , Apoptosis/drug effects , Piperidines/pharmacology , Oxidative Stress/drug effects , Epithelial Cells/drug effects , Epithelial Cells/metabolism , Conjunctiva/drug effects , Conjunctiva/metabolism , Conjunctiva/pathology , Caspase 7/metabolism , Reactive Oxygen Species/metabolism , Conjunctivitis, Allergic/drug therapy , Conjunctivitis, Allergic/pathology , Conjunctivitis, Allergic/metabolism , Phthalazines/pharmacology , Osmolar Concentration , Epithelium, Corneal/drug effects , Epithelium, Corneal/metabolism , Cells, Cultured , Viscosity
16.
J Agric Food Chem ; 72(19): 11185-11194, 2024 May 15.
Article in English | MEDLINE | ID: mdl-38687832

ABSTRACT

Aspergillus flavus contamination in agriculture and food industries poses threats to human health, leading to a requirement of a safe and effective method to control fungal contamination. Chitosan-based nitrogen-containing derivatives have attracted much attention due to their safety and enhanced antimicrobial applications. Herein, a new benzimidazole-grafted chitosan (BAC) was synthesized by linking the chitosan (CS) with a simple benzimidazole compound, 2-benzimidazolepropionic acid (BA). The characterization of BAC was confirmed by Fourier transform infrared (FTIR) spectroscopy and nuclear magnetic resonance spectroscopy (1H and 13C NMR). Then, the efficiency of BAC against A. flavus ACCC 32656 was investigated in terms of spore germination, mycelial growth, and aflatoxin production. BAC showed a much better antifungal effect than CS and BA. The minimum inhibitory concentration (MIC) value was 1.25 mg/mL for BAC, while the highest solubility of CS (16.0 mg/mL) or BA (4.0 mg/mL) could not completely inhibit the growth of A. flavus. Furthermore, results showed that BAC inhibited spore germination and elongation by affecting ergosterol biosynthesis and the cell membrane integrity, leading to the permeabilization of the plasma membrane and leakage of intracellular content. The production of aflatoxin was also inhibited when treated with BAC. These findings indicate that benzimidazole-derived natural CS has the potential to be used as an ideal antifungal agent for food preservation.


Subject(s)
Aspergillus flavus , Benzimidazoles , Chitosan , Fungicides, Industrial , Microbial Sensitivity Tests , Aspergillus flavus/drug effects , Aspergillus flavus/growth & development , Benzimidazoles/pharmacology , Benzimidazoles/chemistry , Benzimidazoles/chemical synthesis , Chitosan/pharmacology , Chitosan/chemistry , Fungicides, Industrial/pharmacology , Fungicides, Industrial/chemistry , Fungicides, Industrial/chemical synthesis , Aflatoxins , Antifungal Agents/pharmacology , Antifungal Agents/chemical synthesis , Antifungal Agents/chemistry , Spores, Fungal/drug effects , Spores, Fungal/growth & development
17.
Adv Mater ; 36(24): e2311760, 2024 Jun.
Article in English | MEDLINE | ID: mdl-38569065

ABSTRACT

Glioblastoma (GBM) is the most aggressive and prevalent primary malignant tumor of the central nervous system. Traditional chemotherapy has poor therapeutic effects and significant side effects due to drug resistance, the natural blood-brain barrier (BBB), and nonspecific distribution, leading to a lack of clinically effective therapeutic drugs. Here, 1430 small molecule compounds are screened based on a high-throughput drug screening platform and a novel anti-GBM drug, lomitapide (LMP) is obtained. Furthermore, a bionic nanodrug delivery system (RFA NPs) actively targeting GBM is constructed, which mainly consists of tetrahedral DNA nanocages (tFNA NPs) loaded with LMP as the core and a folate-modified erythrocyte-cancer cell-macrophage hybrid membrane (FRUR) as the shell. FRUR camouflage conferred unique features on tFNA NPs, including excellent biocompatibility, improved pharmacokinetic profile, efficient BBB permeability, and tumor targeting ability. The results show that the LMP RFA NPs exhibited superior and specific anti-GBM activities, reduced off-target drug delivery, prolonged lifespan, and has negligible side effects in tumor-bearing mice. This study combines high-throughput drug screening with biomimetic nanodrug delivery system technology to provide a theoretical and practical basis for drug development and the optimization of clinical treatment strategies for GBM treatment.


Subject(s)
DNA , Glioblastoma , Glioblastoma/drug therapy , Glioblastoma/pathology , Glioblastoma/metabolism , Animals , Mice , Humans , DNA/chemistry , Cell Line, Tumor , Blood-Brain Barrier/metabolism , Nanostructures/chemistry , Antineoplastic Agents/chemistry , Antineoplastic Agents/pharmacology , Drug Carriers/chemistry , Benzimidazoles/chemistry , Brain Neoplasms/drug therapy , Brain Neoplasms/pathology
18.
Rapid Commun Mass Spectrom ; 38(13): e9751, 2024 Jul 15.
Article in English | MEDLINE | ID: mdl-38680091

ABSTRACT

RATIONALE: With the development of matrix-assisted laser desorption/ionisation (MALDI) mass spectrometry (MS) in spatial localisation omics research on small molecules, the detection sensitivity of the matrix must increase. However, the types of matrices suitable for detecting acidic small molecules in (-) MALDI-MS mode are very limited and are either not sensitive enough or difficult to obtain. METHODS: More than 10 commercially available benzimidazole and benzothiazole derivatives were selected as MALDI matrices in negative ion mode. MALDI-MS analysis was performed on 38 acidic small molecules and mouse serum, and the matrix effects were compared with those of the common commercial matrices 9-aminoacridine (9AA), 1,5-naphthalenediamine (DAN) and 3-aminoquinoline (3AQ). Moreover, the proton affinity (PA) of the selected potential matrix was calculated, and the relationships among the compound structure, PA value and matrix effect were discussed. RESULTS: In (-) MALDI-MS mode, a higher PA value generally indicates a better matrix effect. Amino-substituted 2-phenyl-1H-benzo[d]imidazole derivatives had well-defined matrix effects on all analytes and were generally superior to the commonly used matrices 9AA, DAN and 3AQ. Among them, 2-(4-(dimethylamino-phenyl)-1H-benzo[d]imidazole-5-amine (E-4) has the best sensitivity and versatility for detecting different analytes and has the best ability to detect fatty acids in mouse serum; moreover, the limit of detection (LOD) of some analytes can reach as low as ng/L. CONCLUSIONS: Compared to 9AA, DAN and 3AQ, matrix E-4 is more effective at detecting low-molecular-weight acidic compounds in (-) MALDI-MS mode, with higher sensitivity and better versatility. In addition, there is a clear correlation between compound structure, PA and matrix effects, which provides a basis for designing more efficient matrices.


Subject(s)
Benzimidazoles , Spectrometry, Mass, Matrix-Assisted Laser Desorption-Ionization , Spectrometry, Mass, Matrix-Assisted Laser Desorption-Ionization/methods , Benzimidazoles/chemistry , Benzimidazoles/blood , Benzimidazoles/analysis , Animals , Mice , Benzothiazoles/chemistry , Benzothiazoles/blood
19.
J Phys Chem B ; 128(18): 4367-4376, 2024 May 09.
Article in English | MEDLINE | ID: mdl-38686959

ABSTRACT

The migration of an electron-loss center (hole) in calf thymus DNA to bisbenzimidazole ligands bound in the minor groove is followed by pulse radiolysis combined with time-resolved spectrophotometry. The initially observed absorption spectrum upon oxidation of DNA by the selenite radical is consistent with spin on cytosine (C), as the GC• pair neutral radical, followed by the spectra of oxidized ligands. The rate of oxidation of bound ligands increased with an increase in the ratio (r) ligands per base pair from 0.005 to 0.04. Both the rate of ligand oxidation and the estimated range of hole transfer (up to 30 DNA base pairs) decrease with the decrease in one-electron reduction potential between the GC• pair neutral radical of ca. 1.54 V and that of the ligand radicals (E0', 0.90-0.99 V). Linear plots of log of the rate of hole transfer versus r give a common intercept at r = 0 and a free energy change of 12.2 ± 0.3 kcal mol-1, ascribed to the GC• pair neutral radical undergoing a structural change, which is in competition to the observed hole transfer along DNA. The rate of hole transfer to the ligands at distance, R, from the GC• pair radical, k2, is described by the relationship k2 = k0 exp(constant/R), where k0 includes the rate constant for surmounting a small barrier.


Subject(s)
Base Pairing , DNA , DNA/chemistry , Free Radicals/chemistry , Oxidation-Reduction , Benzimidazoles/chemistry , Animals , Cattle , Ligands , Bisbenzimidazole/chemistry , DNA Repair , DNA Damage , Cytosine/chemistry
20.
Bioorg Chem ; 147: 107326, 2024 Jun.
Article in English | MEDLINE | ID: mdl-38653153

ABSTRACT

Continuing our research into the anticancer properties of acrylonitriles, we present a study involving the design, synthesis, computational analysis, and biological assessment of novel acrylonitriles derived from methoxy, hydroxy, and N-substituted benzazole. Our aim was to examine how varying the number of methoxy and hydroxy groups, as well as the N-substituents on the benzimidazole core, influences their biological activity. The newly synthesized acrylonitriles exhibited strong and selective antiproliferative effects against the Capan-1 pancreatic adenocarcinoma cell line, with IC50 values ranging from 1.2 to 5.3 µM. Consequently, these compounds were further evaluated in three other pancreatic adenocarcinoma cell lines, while their impact on normal PBMC cells was also investigated to determine selectivity. Among these compounds, the monohydroxy-substituted benzimidazole derivative 27 emerged with the most profound and broad-spectrum anticancer antiproliferative activity being emerged as a promising lead candidate. Moreover, a majority of the acrylonitriles in this series exhibited significant antioxidative activity, surpassing that of the reference molecule BHT, as demonstrated by the FRAP assay (ranging from 3200 to 5235 mmolFe2+/mmolC). Computational analysis highlighted the prevalence of electron ionization in conferring antioxidant properties, with computed ionization energies correlating well with observed activities.


Subject(s)
Acrylonitrile , Antineoplastic Agents , Antioxidants , Cell Proliferation , Dose-Response Relationship, Drug , Drug Screening Assays, Antitumor , Pancreatic Neoplasms , Antineoplastic Agents/pharmacology , Antineoplastic Agents/chemistry , Antineoplastic Agents/chemical synthesis , Cell Proliferation/drug effects , Humans , Acrylonitrile/chemistry , Acrylonitrile/pharmacology , Acrylonitrile/analogs & derivatives , Acrylonitrile/chemical synthesis , Pancreatic Neoplasms/drug therapy , Pancreatic Neoplasms/pathology , Structure-Activity Relationship , Molecular Structure , Antioxidants/pharmacology , Antioxidants/chemistry , Antioxidants/chemical synthesis , Adenocarcinoma/drug therapy , Adenocarcinoma/pathology , Cell Line, Tumor , Benzimidazoles/chemistry , Benzimidazoles/pharmacology , Benzimidazoles/chemical synthesis
SELECTION OF CITATIONS
SEARCH DETAIL
...